Akadeum Life Sciences, the leader in buoyant microbubble cell separation, today announced that its Chief Executive Officer Brandon McNaughton, PhD, will present at Biotech Showcase (TM) 2026 in San ...

CAR-T therapy is a major advance in cancer care, but high costs and centralized global manufacturing limit access.

Autolus Therapeutics is working with Cellares to assess automated CAR T manufacturing to support rising demand for its ...

Next-generation automation is closing the gap between curative science and real-world demand, enabling faster development, ...

- Joint venture will aim to develop a cell therapy manufacturing platform through robotics and will offer access to startups and academic institutions - In the pharmaceutical industry, the ...

The AMT designation gives Cellares’ clients using the Cell Shuttle priority review with the FDA leading to accelerated regulatory filings SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Cellares, the ...

With the power of robotics and the personalized medicine expertise of one of Japan's top drugmakers, Astellas Pharma and Yaskawa Electric Corporation are setting off on a joint venture to help ...

Under the service agreement, BOOST Pharma has transferred its manufacturing process to RoslinCT’s state-of-the-art facilities in Edinburgh, Scotland. The partnership will progress toward GMP ...

Technology Adoption Program (TAP) program success demonstrates the ability of Cellares’ IDMO Smart Factory to automate, lower costs and scale out manufacturing for Cabaletta Bio’s clinical-stage CAR T ...

ASPIRO is the first multi-patient, multi-center clinical trial of an autologous cell therapy for Parkinson's disease. It is evaluating safety, tolerability, and preliminary efficacy of ANPD001 in ...

The first half of 2025 has been a notable one for Cellares. The cell therapy manufacturer operates its first commercial-scale Integrated Development and Manufacturing Organization Smart Factory in ...

Controlling the entire cell therapy production process—from material receipt to product release—is “essential,” according to AstraZeneca, which says its new $300 million manufacturing facility will be ...